10.19.21
Autolomous LTD, a developer of critical manufacturing management systems for cell and gene therapies, and Vineti, a provider of digital enterprise platforms for cell and gene therapy supply chains, have entered a collaboration to integrate Autolomous’ critical manufacturing management systems with Vineti’s Personalized Therapy Management (PTM) platform.
The collaboration aims to enable both parties to create a seamless end-to-end cell and gene therapy (CGT) delivery pathway including critical inbound and outbound manufacturing value processes. The companies aim to increase the visibility and exchange of information to and from stakeholders across the cell and gene therapy value chain. This aims to ensure they can react to unpredictable variables related to working on biological processes. Furthermore, the integration of the technologies will enable scaling up of manufacturing by increasing transparency, compliance and auditability whilst delivering significant savings in time and resources from efficiency gains.
This will be the first time Autolomous’ manufacturing focused platform will be integrated with a Cell Orchestration Platform (COP), which is an integral part of Autolomous’ long-term strategy to provide support across the entire CGT value chain. This collaboration follows the receipt by Autolomous and partners of a joint GBP 1 million project grant from UK Research and Innovation (UKRI) to enhance the scheduling and manufacturing of advanced therapies within the UK’s NHS, for the UK’s Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC).
As part of the project Autolomous will provide an industry-first demonstration of an electronic Batch Manufacturing Record (eBMR) solution integrating with a dedicated NHS advanced therapies ordering system. It also follows Autolomous’ receipt of a loan from UK Research and Innovation (UKRI) to expedite development of AutoloMATE-Assist, its digital batch verification technology for cell and gene therapies. Once completed, Autolomous will take this UK healthcare provision model and expand this to the U.S. and other major national healthcare networks globally.
The first stage of the integration between Autolomous and Vineti will be a live implementation of Vineti’s notifications API. This will enable users of Autolomous’ AutoloMATE service platform to action orders as soon as they are created and throughout the entire lifecycle of the order. The integration will allow manufacturing teams to optimize the manufacturing capacity. Unplanned and unexpected changes within the supply chain, such as cancellations, rescheduling and manufacturing delays will be communicated across technology and systems from Autolomous and Vineti. Once this first stage is completed, Autolomous and Vineti will demonstrate a technical proof of concept in 3Q21 and implement this integration with an existing customer of both organizations in 2022.
The collaboration aims to enable both parties to create a seamless end-to-end cell and gene therapy (CGT) delivery pathway including critical inbound and outbound manufacturing value processes. The companies aim to increase the visibility and exchange of information to and from stakeholders across the cell and gene therapy value chain. This aims to ensure they can react to unpredictable variables related to working on biological processes. Furthermore, the integration of the technologies will enable scaling up of manufacturing by increasing transparency, compliance and auditability whilst delivering significant savings in time and resources from efficiency gains.
This will be the first time Autolomous’ manufacturing focused platform will be integrated with a Cell Orchestration Platform (COP), which is an integral part of Autolomous’ long-term strategy to provide support across the entire CGT value chain. This collaboration follows the receipt by Autolomous and partners of a joint GBP 1 million project grant from UK Research and Innovation (UKRI) to enhance the scheduling and manufacturing of advanced therapies within the UK’s NHS, for the UK’s Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC).
As part of the project Autolomous will provide an industry-first demonstration of an electronic Batch Manufacturing Record (eBMR) solution integrating with a dedicated NHS advanced therapies ordering system. It also follows Autolomous’ receipt of a loan from UK Research and Innovation (UKRI) to expedite development of AutoloMATE-Assist, its digital batch verification technology for cell and gene therapies. Once completed, Autolomous will take this UK healthcare provision model and expand this to the U.S. and other major national healthcare networks globally.
The first stage of the integration between Autolomous and Vineti will be a live implementation of Vineti’s notifications API. This will enable users of Autolomous’ AutoloMATE service platform to action orders as soon as they are created and throughout the entire lifecycle of the order. The integration will allow manufacturing teams to optimize the manufacturing capacity. Unplanned and unexpected changes within the supply chain, such as cancellations, rescheduling and manufacturing delays will be communicated across technology and systems from Autolomous and Vineti. Once this first stage is completed, Autolomous and Vineti will demonstrate a technical proof of concept in 3Q21 and implement this integration with an existing customer of both organizations in 2022.